Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
262.4 ^USD	+1.65%		+12.21%	+19.33%

03/05	United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	MT
02/05	UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	04/05	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	02/05	MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating	02/05	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	20/04	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	18/04	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	16/04	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	12/04	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	10/04	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	06/04	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	05/04	MT
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	26/03	MT
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	23/03	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	22/03	MT
Goldman Sachs Upgrades United Therapeutics to Neutral From Sell, Adjusts PT to $215 From $213	12/02	MT
Leerink Partners Starts United Therapeutics with Outperform Rating, $330 Price Target	05/02	MT
Wedbush Lifts United Therapeutics' PT to $308 From $307 After Higher-Than-Expected Q3 Revenue Driven by Tivaso Franchise; Keeps Outperform Rating	02/11	MT
Morgan Stanley Adjusts Price Target on United Therapeutics to $318 From $316, Maintains Overweight Rating	03/23/03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $268 From $256, Maintains Buy Rating	03/23/03	MT
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating	03/23/03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $256 From $285, Maintains Buy Rating	04/23/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Analyst Reco.

Filters